Business Context and Reporting Period
This Form 8-K is a current report filed by TherapeuticsMD, Inc. (Nasdaq: TXMD) on January 6, 2023. The filing addresses a regulatory compliance issue regarding the company's continued listing on the Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing status rather than financial performance.
Material Changes
The material event reported is the receipt of a deficiency letter from Nasdaq on January 6, 2023. The company is in non-compliance with Nasdaq Listing Rule 5620(a) (the "Annual Meeting Rule") because it failed to hold an annual meeting of stockholders within 12 months following its fiscal year end of December 31, 2021. The company attributes this failure to ongoing strategic processes during 2022.
Outlook, Risks, and Management Commentary
- Compliance Plan: The company has 45 calendar days (until February 20, 2023) to submit a plan to regain compliance. If accepted, Nasdaq may grant an extension of up to 180 days from the fiscal year end (until June 29, 2023) to hold the meeting.
- Management Intent: Management intends to submit a plan to hold the 2022 annual meeting prior to June 29, 2023.
- Risks: There is no assurance that Nasdaq will accept the plan or that an appeal to a Hearings Panel would be successful if the plan is rejected. However, the notice has no immediate effect on the listing of the common stock.
Investor Verification Checklist
- Verify the submission date of the compliance plan to Nasdaq (deadline: February 20, 2023).
- Monitor for Nasdaq's acceptance or rejection of the proposed compliance plan.
- Confirm the scheduled date for the 2022 annual meeting of stockholders.
- Review subsequent filings for updates on the company's "ongoing strategic processes" that caused the delay.